Influence of subcutaneous specific immunotherapy on drug costs in children sufferingfrom allergic asthma

Clinical and Translational Allergy

Volumn 3, Issue 1, 2013, Pages 1-8

  Reinhold, Thomas ^a   Ostermann, Julia ^a   Thum Oltmer, Susanne ^b   Brüggenjürgen, Bernd ^a,c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b ALLERGOPHARMA JOACHIM GANZER KG   (Germany)

^c STEINBEIS UNIVERSITY BERLIN   (Germany)

Author keywords

Asthma; Cost effectiveness analysis; High dose hypoallergenic mite preparation; Subcutaneous specific immunotherapy

Indexed keywords

HOUSE DUST ALLERGEN;

ALLERGIC ASTHMA; ARTICLE; CHILD; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DERMATOPHAGOIDES; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SUBCUTANEOUS IMMUNOTHERAPY; TREATMENT OUTCOME;

EID: 85006100947     PISSN: None     EISSN: 20457022     Source Type: Journal    
DOI: 10.1186/2045-7022-3-30     Document Type: Article

References (29)

1. Masoli M, Fabian D, Holt S, Beasley R: Review article: The global burden of asthma: executive summary of the GINADissemination Committee Report. Allergy. 2004, 59 (5): 469-478. 10.1111/j.1398-9995.2004.00526.x.
2. Stock S, Redaelli M, Luengen M, Wendland G, Civello D, Lauterbach KW: Asthma: prevalence and cost of illness. Eur Respir J : official journal of the European Society for Clinical RespiratoryPhysiology. 2005, 25: 47-53. 10.1183/09031936.04.00116203.
3. Schlaud M, Atzpodien K, Thierfelder W: [Allergic diseases. Results from the German Health Interview and ExaminationSurvey for Children and Adolescents (KiGGS)]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2007, 50: 701-710. 10.1007/s00103-007-0231-9.
4. Matterne U, Schmitt J, Diepgen TL, Apfelbacher C: Children and adolescents’ health-related quality of life in relation toeczema, asthma and hay fever: results from a population-based cross-sectionalstudy. Qual Life Res. 2011, 20: 1295-1305. 10.1007/s11136-011-9868-9.
5. O’Connell E: The burden of atopy and asthma in children. Allergy. 2004, 59: 7-11. 10.1111/j.1398-9995.2004.00563.x.
6. Weißflog D, Matthys H, Virchow JC: Epidemiologie und Kosten von Asthma bronchiale und chronischer Bronchitis inDeutschland. Dtsch Med Wochenschr. 2001, 126: 803-808. 10.1055/s-2001-15705.
7. Böcking C, Renz H, Pfefferle PI: Prävalenz und sozioökonomische Bedeutung von Allergien inDeutschland. Bundesgesundheitsbl. 2012, 55: 303-307. 10.1007/s00103-011-1427-6.
8. Gillissen A, Bergmann K-C, Kleine-Tebbe J, Schultze-Werninghaus G, Virchowjun JC, Wahn U, Graf v.d Schulenburg J-M: Die Bedeutung der spezifischen Immuntherapie bei allergischem Asthma bronchialeSpecific immunotherapy in allergic asthma. Dtsch Med Wochenschr. 2003, 128 (5): 204-209. 10.1055/s-2003-36983.
9. Holgate ST, Polosa R: Treatment strategies for allergy and asthma. Nat Rev Immunol. 2008, 8: 218-230. 10.1038/nri2262.
10. Abramson M, Puy R, Weiner J: Injection allergen immunotherapy for asthma (Review). Cochrane Database Syst Rev. 2010, Issue 8. Art. No.: CD001186
11. Westerhout KY, Verheggen BG, Schreder CH, Augustin M: Cost effectiveness analysis of immunotherapy in patients with grass pollenallergic rhinoconjunctivitis in Germany. J Med Econ. 2012, 15: 906-917. 10.3111/13696998.2012.688904.
12. Brüggenjürgen B, Reinhold T, Brehler R, Laake E, Wiese G, Machate U, Willich SN: Cost-effectiveness of specific subcutaneous immunotherapy in patients withallergic rhinitis and allergic asthma. Ann Allergy Asthma Immunol. 2008, 101: 316-324. 10.1016/S1081-1206(10)60498-X.
13. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, Gibson P, Ohta K, O’Byrne P, Pedersen SE, Pizzichini E, Sullivan SD, Wenzel SE, Zar HJ: Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008, 31: 143-178. 10.1183/09031936.00138707.
14. Rudert M, Kettner J, Haefner D, Narkus A, Thum-Oltmer S: Effects of the third year of specific immunotherapy with a high-dosehypoallergenic house dust mite preparation in children with allergic asthma. Allergy. 2012, 67: 525-
15. Zielen S, Kardos P, Madonini E: Steroid-sparing effects with allergen-specific immunotherapy in children withasthma: a randomized controlled trial. J Allergy Clin Immunol. 2010, 126: 942-949. 10.1016/j.jaci.2010.06.002.
16. Rote L: Arzneimittelinformationen für Deutschland.http://www.rote-liste.de/,
17. Schwabe U, Paffrath D: Arzneiverordnungsreport. 2012, Berlin, Heidelberg: Springer Medizin Verlag
18. Henderson AR: The bootstrap: a technique for data-driven statistics. Using computer-intensiveanalyses to explore experimental data. Clin Chim Acta. 2005, 359 (1-2): 1-26. 10.1016/j.cccn.2005.04.002.
19. Mckee M, Britton A, Black N, Mcpherson K, Sanderson C, Bain C: Interpreting the evidence: choosing between randomised and non-randomisedstudies. BMJ. 1999, 319: 312-315.
20. Chipps BE, Zeiger RS, Dorenbaum A, Borish L, Wenzel SE, Miller DP, Hayden ML, Bleecker ER, Simons FER, Szefler SJ, Weiss ST, Haselkorn T: Assessment of asthma control and asthma exacerbations in the epidemiology andnatural history of asthma: outcomes and treatment regimens (TENOR) observationalcohort. Cur respir care rep. 2012, 1: 259-269. 10.1007/s13665-012-0025-x.
21. Haselkorn T, Fish JE, Zeiger RS, Szefler SJ, Miller DP, Chipps BE, Simons FER, Weiss ST, Wenzel SE, Borish L, Bleecker ER: Consistently very poorly controlled asthma, as defined by the impairment domain ofthe Expert Panel Report 3 guidelines, increases risk for future severe asthmaexacerbations in the epidemiology and natural history of asthma: outcomes andtreatment regime. J Allergy Clin Immunol. 2009, 124: 895-902. 10.1016/j.jaci.2009.07.035. e1-4,
22. Sims EJ, Price D, Haughney J, Ryan D, Thomas M: Current control and future risk in asthma management. Allergy Asthma Immunol Res. 2011, 3: 217-225. 10.4168/aair.2011.3.4.217.
23. Al-Jahdali H, Anwar A, Al-Harbi A, Baharoon S, Halwani R, Al Shimemeri A, Al-Muhsen S: Factors associated with patient visits to the emergency department for asthmatherapy. BMC Pulm Med. 2012, 12: 80-10.1186/1471-2466-12-80.
24. Bateman ED, Bousquet J, Busse WW, Clark TJH, Gul N, Gibbs M, Pedersen S: Stability of asthma control with regular treatment: an analysis of the GainingOptimal Asthma controL (GOAL) study. Allergy. 2008, 63: 932-938. 10.1111/j.1398-9995.2008.01724.x.
25. Ivanova JI, Bergman R, Birnbaum HG, Colice GL, Silverman RA, McLaurin K: Effect of asthma exacerbations on health care costs among asthmatic patients withmoderate and severe persistent asthma. J Allergy Clin Immunol. 2012, 129: 1229-1235. 10.1016/j.jaci.2012.01.039.
26. Kelly HW, Sternberg AL, Lescher R, Fuhlbrigge AL, Williams P, Zeiger RS, Raissy HH, Van Natta ML, Tonascia J, Strunk RC: Effect of inhaled glucocorticoids in childhood on adult height. New Engl Jj Med. 2012, 367: 904-912. 10.1056/NEJMoa1203229.
27. Calpin C, Macarthur C, Stephens D, Feldmann W, Parkin P: Effectiveness of prophylactic inhaled steroids in childhood asthma: a systematicreview of the literature. J Allergy Clin Immunol. 1997, 100: 452-457. 10.1016/S0091-6749(97)70134-9.
28. Larenas-Linnemann DES, Pietropaolo-Cienfuegos DR, Calderón MA: Evidence of effect of subcutaneous immunotherapy in children: complete and updatedreview from 2006 onward. Annals of Allergy, Asthma Immunol. 2011, 107: 407-416. 10.1016/j.anai.2011.07.018. e11,
29. Drummond MF, O’Brien B, Stoddart GL, Torrance GW: Methods for the Economic Evaluation of Health Care Programmes. 1997, New York: Oxford University Press, 2